Late last year, Novo Nordisk responded to a ... Novo has cracked down on those sellers with trademark infringement lawsuits and settled with two Florida sellers in February. Novo's GLP-1 rival ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Under the agreement, Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases and up to five additional future targets ...

Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies. Korro Bio NewsMORE Related Stocks ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Novo Nordisk is continuing its push into genetic ... technology in the development of two base-editing therapies in rare genetic diseases. The deal covers up to five more targets in rare and ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies. About Korro Korro is a ...

On Wednesday, Cantor Fitzgerald reaffirmed its positive stance on Novo Nordisk (NYSE:NVO), maintaining an Overweight rating and a price target of $160.00. The reaffirmation came as Novo Nordisk ...

Participants who took two 50-mg pills daily lost 13.1% of their weight compared to 1.1% in the placebo group for both doses. According to Novo Nordisk, the drug is safe, with side effects in line ...